company background image
CPRX logo

Catalyst Pharmaceuticals NasdaqCM:CPRX Stock Report

Last Price

US$16.27

Market Cap

US$1.9b

7D

-3.8%

1Y

-2.7%

Updated

27 Mar, 2024

Data

Company Financials +

Catalyst Pharmaceuticals, Inc.

NasdaqCM:CPRX Stock Report

Market Cap: US$1.9b

CPRX Stock Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

CPRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Catalyst Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.27
52 Week HighUS$18.22
52 Week LowUS$11.09
Beta0.93
1 Month Change14.74%
3 Month Change-5.41%
1 Year Change-2.69%
3 Year Change252.93%
5 Year Change210.50%
Change since IPO166.72%

Recent News & Updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27
Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13
Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Sep 12

Catalyst Pharma ends momentum as Roth downgrades

Aug 24

Catalyst Pharmaceuticals: Performing Above Expectations

Aug 12

Catalyst: Upside Outlier - In Search Of A Catalyst

May 11

Catalyst: A Classic Case Of Watch That Basket

Jan 20

Shareholder Returns

CPRXUS BiotechsUS Market
7D-3.8%0.9%0.4%
1Y-2.7%10.3%28.8%

Return vs Industry: CPRX underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: CPRX underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement7.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CPRX has not had significant price volatility in the past 3 months.

Volatility Over Time: CPRX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002167Rich Dalyhttps://www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.

Catalyst Pharmaceuticals, Inc. Fundamentals Summary

How do Catalyst Pharmaceuticals's earnings and revenue compare to its market cap?
CPRX fundamental statistics
Market capUS$1.92b
Earnings (TTM)US$71.41m
Revenue (TTM)US$398.20m

26.9x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CPRX income statement (TTM)
RevenueUS$398.20m
Cost of RevenueUS$145.12m
Gross ProfitUS$253.09m
Other ExpensesUS$181.68m
EarningsUS$71.41m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.61
Gross Margin63.56%
Net Profit Margin17.93%
Debt/Equity Ratio0%

How did CPRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.